



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/738883/2013

European Medicines Agency decision

P/0002/2014

of 21 January 2014

on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (EMA-000380-PIP02-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0002/2014

of 21 January 2014

on the acceptance of a modification of an agreed paediatric investigation plan for secukinumab (EMA-000380-PIP02-09-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/141/2010 issued on 30 July 2010,

Having regard to the application submitted by Novartis Europharm Limited on 16 September 2013 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 December 2013, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for secukinumab, powder for solution for injection or infusion, subcutaneous use, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Limited, Wimblehurst Road, RH12 5AB - Horsham, United Kingdom.

Done at London, 21 January 2014

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/600083/2013

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMA-000380-PIP02-09-M01

Scope of the application

Active substance(s):

Secukinumab

Condition(s):

Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

Pharmaceutical form(s):

Powder for solution for injection or infusion

Route(s) of administration:

Subcutaneous use

Intravenous use

Name / corporate name of the PIP applicant:

Novartis Europharm Limited

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Limited submitted to the European Medicines Agency on 16 September 2013 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/141/2010 issued on 30 July 2010.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 10 October 2013.

Scope of the modification

The name of the active substance and the name of the condition have been changed. Timelines of one measure of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

London, 6 December 2013

On behalf of the Paediatric Committee
Dr Dirk Mentzer, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

The waiver applies to:

- children from birth to less than 2 years;
- for powder for solution for injection or infusion for subcutaneous use and intravenous use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition: treatment of chronic idiopathic arthritis (including rheumatoid arthritis, spondyloarthritis, psoriatic arthritis and juvenile idiopathic arthritis)

2.1.1. Indication(s) targeted by the PIP

Treatment of juvenile idiopathic arthritis (extended oligoarthritis, RF+ polyarthritis, RF- polyarthritis, systemic JIA without systemic manifestations and polyarticular course, enthesitis related arthritis, psoriatic arthritis)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for injection or infusion

2.1.4. Measures

Area	Number of measures	Description
Quality	1	Measure 1 Development of age appropriate formulation for intravenous use or subcutaneous use
Non-clinical	0	Not applicable.

Clinical	2	Measure 2 Population pharmacokinetic modelling Measure 3 Multicentre double-blind three arm two-dose randomised placebo controlled withdrawal study to evaluate efficacy and safety of AIN457 in children with juvenile idiopathic arthritis
----------	---	--

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2018
Deferral for one or more measures contained in the paediatric investigation plan:	Yes